Your browser doesn't support javascript.
loading
Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet's disease.
Kim, H J; Kim, K-T; Lee, S-G; Kim, Y.
Afiliação
  • Kim HJ; Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-Ro Seo-Gu, 49267, Busan, Korea (Republic of).
  • Kim KT; Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-Ro Seo-Gu, 49267, Busan, Korea (Republic of).
  • Lee SG; Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea (Republic of).
  • Kim Y; Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-Ro Seo-Gu, 49267, Busan, Korea (Republic of). efmsungmo@hanmail.net.
Z Rheumatol ; 79(7): 702-706, 2020 Sep.
Article em En | MEDLINE | ID: mdl-32494950
Behçet's disease (BD) is a recurrent, multisystemic, inflammatory blood vessel disorder that can result in mouth, genital, and skin ulcers; arthritis; and eye and intestinal inflammation. We describe a 21-year-old Korean female patient with intestinal BD refractory to conventional medical treatment and biologic drugs. The patient was initially treated with high-dose steroids and sulfasalazine. Two months later, a skin rash occurred as a side effect of sulfasalazine. Therefore, infliximab (IFX) was administered, and disease activity decreased. However, IFX also induced a skin rash; hence, the patient was switched to adalimumab. After 12 months, the patient experienced a relapse of intestinal BD. Hence, treatment was initiated using a combination of methotrexate and adalimumab; however, this treatment was ineffective. Methotrexate was discontinued and replaced with 5­aminosalicylic acid while maintaining adalimumab, and no recurrence has been observed to date. We report this novel strategy involving the use of anti-tumor necrosis factor­α agents for patients with resistant BD; however, further large cohort studies are required to verify its usefulness.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome de Behçet / Mesalamina / Adalimumab Tipo de estudo: Observational_studies Limite: Adult / Female / Humans Idioma: En Revista: Z Rheumatol Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome de Behçet / Mesalamina / Adalimumab Tipo de estudo: Observational_studies Limite: Adult / Female / Humans Idioma: En Revista: Z Rheumatol Ano de publicação: 2020 Tipo de documento: Article